Insider Transactions in Q3 2025 at Syndax Pharmaceuticals Inc (SNDX)
Insider Transaction List (Q3 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 08
2025
|
Michael A Metzger Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
157,307
-34.5%
|
$2,516,912
$16.41 P/Share
|
|
Sep 08
2025
|
Michael A Metzger Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
157,307
+25.65%
|
$1,573,070
$10.9 P/Share
|
|
Aug 18
2025
|
Dennis Podlesak |
SELL
Open market or private sale
|
Direct |
19,200
-9.1%
|
$288,000
$15.84 P/Share
|
|
Aug 18
2025
|
Dennis Podlesak |
BUY
Exercise of conversion of derivative security
|
Direct |
19,200
+8.34%
|
$134,400
$7.2 P/Share
|
|
Aug 15
2025
|
Dennis Podlesak |
SELL
Open market or private sale
|
Direct |
19,200
-9.1%
|
$288,000
$15.54 P/Share
|
|
Aug 15
2025
|
Dennis Podlesak |
BUY
Exercise of conversion of derivative security
|
Direct |
19,200
+8.34%
|
$134,400
$7.2 P/Share
|
|
Aug 14
2025
|
Dennis Podlesak |
SELL
Open market or private sale
|
Direct |
19,200
-9.1%
|
$268,800
$14.19 P/Share
|
|
Aug 14
2025
|
Dennis Podlesak |
BUY
Exercise of conversion of derivative security
|
Direct |
19,200
+8.34%
|
$134,400
$7.2 P/Share
|
|
Jul 31
2025
|
Keith A. Goldan Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
1,226
+1.29%
|
$9,808
$8.43 P/Share
|
|
Jul 16
2025
|
Michael A Metzger Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,534
-2.46%
|
$67,806
$9.29 P/Share
|
|
Jul 16
2025
|
Keith A. Goldan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,296
-1.38%
|
$11,664
$9.29 P/Share
|